Skip Header
Important information: The value of investments can go down as well as up so you may get back less than you invest. Investors should note that the views expressed may no longer be current and may have already been acted upon. This is a third-party news feed and may not reflect Fidelity’s views.

MONY sees jump in full-year profit, raises dividend and unveils share buyback

(Sharecast News) - MONY Group boosted its full-year profits, which allowed it to improve its shareholder returns. The owner of money-saving platforms said that its profit rose by 11% to £80.2m on an after tax basis, while the operating profit in EBITDA terms was ahead by 7% to £141.8m.

Topline growth meanwhile was pegged at 2% to reach £439.2m.

Company boss Peter Duffy highlighted how the company had helped customers save a record £2.9bn.

He also noted how the group had encouraged clients to join its member-based propositions such as SuperSave Club, which had in turn allowed it to reduce its increasingly costly pay-per-click marketing.

The company also said it was confident in its ability to achieve adjusted EBITDA growth for 2025 in line with its published consensus.

That was despite "headwinds" in the car insurance switching market.

They also highlighted their ongoing focus on mitigating cost inflation.

Operating cash flow during the period increased 13% to £115.6m and MONY swang to a net cash position of £8.4m.

The dividend per share was raised by 3% to 9.2p for a full-year payout of 12.5p.

Management also unveiled a share buyback programme of up to £30m.

Share this article

Related Sharecast Articles

GSK gets preliminary nod for two respiratory drugs in Europe
(Sharecast News) - GSK said on Friday afternoon that two of its respiratory medicines had received positive opinions from the European Medicines Agency's Committee for Medicinal Products for Human Use, bringing the company closer to potential approvals across severe asthma, chronic rhinosinusitis with nasal polyps and chronic obstructive pulmonary disease.
Shore Capital hails improved US biotech funding environment for hVIVO
(Sharecast News) - Shares in AIM-listed hVIVO were continuing their recent surge on the back of encouraging signs from the US biotech market, which broker Shore Capital said has created a "much more favourable environment" for the company.
Weir to buy remaining 50% stake in Chile JV ESEL for £56m
(Sharecast News) - Weir said on Friday that it has agreed to buy the remaining 50% share of its Chile-based joint venture ESEL for a sterling equivalent purchase price of £56m.
Jefferies downgrades Whitbread, upgrades IHG
(Sharecast News) - Jefferies downgraded Whitbread to 'hold' from 'buy' on Friday as it applied the reverse upgrade to InterContinental Hotels.

Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.

Award-winning online share dealing

Search, compare and select from thousands of shares.

Expert insights into investing your money

Our team of experts explore the world of share dealing.